Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BTMD
stocks logo

BTMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
45.79M
-8.12%
0.020
-80%
47.51M
-3.03%
0.055
-85.14%
49.61M
+1.54%
0.070
-30%
Estimates Revision
The market is revising Downward the revenue expectations for biote Corp. (BTMD) for FY2025, with the revenue forecasts being adjusted by -0.41% over the past three months. During the same period, the stock price has changed by -25.72%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.41%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+12.5%
In Past 3 Month
Stock Price
Go Down
down Image
-25.72%
In Past 3 Month
Wall Street analysts forecast BTMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTMD is 3.67 USD with a low forecast of 3.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BTMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTMD is 3.67 USD with a low forecast of 3.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.570
sliders
Low
3.00
Averages
3.67
High
4.50
Current: 2.570
sliders
Low
3.00
Averages
3.67
High
4.50
B. Riley
Jeff Van Sinderen
Neutral
downgrade
$4 -> $3
2025-11-06
Reason
B. Riley
Jeff Van Sinderen
Price Target
$4 -> $3
2025-11-06
downgrade
Neutral
Reason
B. Riley analyst Jeff Van Sinderen lowered the firm's price target on Biote to $3 from $4 and keeps a Neutral rating on the shares. The firm reduced estimates post the Q3 report.
B. Riley
B. Riley
Buy -> Neutral
downgrade
$8 -> $4
2025-08-07
Reason
B. Riley
B. Riley
Price Target
$8 -> $4
2025-08-07
downgrade
Buy -> Neutral
Reason
B. Riley downgraded Biote to Neutral from Buy with a price target of $4, down from $8.
B. Riley
Jeff Van Sinderen
Buy -> Neutral
downgrade
$8 -> $4
2025-08-07
Reason
B. Riley
Jeff Van Sinderen
Price Target
$8 -> $4
2025-08-07
downgrade
Buy -> Neutral
Reason
B. Riley analyst Jeff Van Sinderen downgraded Biote to Neutral from Buy with a price target of $4, down from $8. The company reported a mixed Q2 and lowered its fiscal 2025 outlook, the analyst tells investors in a research note. The firm says a high attrition rate of established clinics, lower procedure volume, and a low rate of new clinic acquisition hindered Biote's Q2. Riley is unsure of the time it will take the company to achieve sustainable growth of quality new practitioner adds and procedures.
TD Cowen
Buy
downgrade
$6 -> $4
2025-05-09
Reason
TD Cowen
Price Target
$6 -> $4
2025-05-09
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Biote to $4 from $6 and keeps a Buy rating on the shares. The firm notes Q1 2025 upside was largely on better supplements growth and higher gross margin from both verticalization and favorable mix and management reiterated full year guide. TD Cowen notes that valuation remains inexpensive, but sees some bumps in the road before starting to see sustained growth. FY25 guide likely builds in conservatism but key to beats and raises will be the progress with new clinic growth, the firm adds.
B. Riley
Jeff Van Sinderen
Buy
downgrade
$9 -> $8
2025-05-09
Reason
B. Riley
Jeff Van Sinderen
Price Target
$9 -> $8
2025-05-09
downgrade
Buy
Reason
B. Riley analyst Jeff Van Sinderen lowered the firm's price target on Biote to $8 from $9 and keeps a Buy rating on the shares. The company's Q1 revenue and adjusted EBITDA came in above expectations, the analyst tells investors in a research note. The firm trimmed the price target to reflect a reduced multiple.
Roth Capital
Buy
downgrade
$8 -> $6
2025-05-08
Reason
Roth Capital
Price Target
$8 -> $6
2025-05-08
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Biote to $6 from $8 and keeps a Buy rating on the shares. The company's Q1 report was again mixed as gross margin exceeded 74% but the revenue outperformance was driven by Biote's lower quality supplement business, the analyst tells investors in a research note. Procedure growth also turned negative and forward growth remains uncertain, the firm adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biote Corp (BTMD.O) is 11.22, compared to its 5-year average forward P/E of 3.95. For a more detailed relative valuation and DCF analysis to assess Biote Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
3.95
Current PE
11.22
Overvalued PE
24.44
Undervalued PE
-16.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
2.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.86
Undervalued EV/EBITDA
0.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.53
Current PS
0.00
Overvalued PS
0.85
Undervalued PS
0.22
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 221.99% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 221.99% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BTMD News & Events

Events Timeline

(ET)
2025-11-05
16:54:55
Biote projects FY25 revenue to exceed $190M, with consensus at $192.73M
select
2025-11-05
16:54:25
Biote Announces Q3 Earnings Per Share of 22 Cents, Exceeding Consensus Estimate of 12 Cents
select
2025-08-06 (ET)
2025-08-06
17:17:51
Biote cuts FY25 revenue view to over $190M from $202M-$208M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-06NASDAQ.COM
Biote Corp Reports Decrease in Q3 Earnings
  • Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
  • Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
  • Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
  • Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
[object Object]
Preview
9.0
09-26NASDAQ.COM
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?

  • Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.

  • Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.

[object Object]
Preview
5.0
06-10Newsfilter
Biote Names Rich Barrera to Board of Directors

  • New Board Member Announcement: Biote Corp. has appointed Rich Barrera to its Board of Directors, bringing over 20 years of investment management experience and alignment with the company's growth strategy.

  • Company Overview: Biote focuses on preventive health care through personalized hormone optimization and wellness solutions, aiming to address aging conditions and enhance clinic success for practitioners.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biote Corp (BTMD) stock price today?

The current price of BTMD is 2.57 USD — it has decreased -0.39 % in the last trading day.

arrow icon

What is Biote Corp (BTMD)'s business?

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

arrow icon

What is the price predicton of BTMD Stock?

Wall Street analysts forecast BTMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTMD is 3.67 USD with a low forecast of 3.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biote Corp (BTMD)'s revenue for the last quarter?

Biote Corp revenue for the last quarter amounts to 47.96M USD, decreased -6.67 % YoY.

arrow icon

What is Biote Corp (BTMD)'s earnings per share (EPS) for the last quarter?

Biote Corp. EPS for the last quarter amounts to 0.22 USD, decreased -33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biote Corp (BTMD)'s fundamentals?

The market is revising Downward the revenue expectations for biote Corp. (BTMD) for FY2025, with the revenue forecasts being adjusted by -0.41% over the past three months. During the same period, the stock price has changed by -25.72%.
arrow icon

How many employees does Biote Corp (BTMD). have?

Biote Corp (BTMD) has 217 emplpoyees as of December 05 2025.

arrow icon

What is Biote Corp (BTMD) market cap?

Today BTMD has the market capitalization of 117.35M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free